Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.53 |
| ▸ | ACACB | O00763 | 4/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476087 | 0.85 | POLB (0.48) | RORC | |
| SCHEMBL1498297 | 0.84 | RORC (0.47) | RORC | |
| SCHEMBL12688377 | 0.84 | RORC (0.47) | RORC | |
| SCHEMBL12688439 | 0.84 | RORC (0.47) | RORC | |
| SCHEMBL12542534 | 0.80 | RORC (0.44) | RORC | |
| SCHEMBL12542202 | 0.80 | LMNA (0.46) | RORCDRD2 | |
| SCHEMBL12688703 | 0.80 | LMNA (0.46) | RORCDRD2 | |
| SCHEMBL12542199 | 0.80 | LMNA (0.46) | RORCDRD2 | |
| SCHEMBL12688574 | 0.80 | RORC (0.44) | RORC | |
| SCHEMBL12692956 | 0.79 | ACACB (0.47) | RORCACACBACACADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | RORC 1695/4885ACACB 2719/4885TGFBR1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.